HYBRID EVENT: Join us in person in Boston, Massachusetts, USA or attend virtually from anywhere.
13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Stem Cells Role in Neuro-Biological Treatment
Stem Cells Role in Neuro-Biological Treatment
Stem cells are incomparable human cells that are able to mature into many different cell types. This can range from muscle cells to brain cells. In some cases, they can also repair damaged tissues. Neural stem cells (NSCs) offer the capability to replace lost tissue after nervous system injury. Thus, stem cells can uplift host neural repair in part by secreting growth factors, and their regeneration-promoting activities can be modified by gene delivery.
- Totipotent (or Omnipotent) Stem Cells
- Pluripotent Stem Cells
- Multipotent Stem Cells
- Oligopotent Stem Cells
- Unipotent Stem Cells
Committee Members
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States INBC 2026 Speakers
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States